Derivation of Vascular Endothelial Cells from Human Embryonic Stem Cells Under GMP-Compliant Conditions: Towards Clinical Studies in Ischaemic Disease
Autor: | Nicole M. Kane, Andrew H. Baker, V. Stelmanis, Alexandra Kaupisch, Joanne C. Mountford, A. Courtney, L. Kennedy, B. Tye |
---|---|
Rok vydání: | 2012 |
Předmět: |
CD31
Cell type Pathology medicine.medical_specialty Time Factors Cellular differentiation Cell Culture Techniques Neovascularization Physiologic Pharmaceutical Science Guidelines as Topic Biology Cell Line Flow cytometry Neovascularization Antigens CD Ischemia Genetics medicine Humans Cell Lineage Therapeutic angiogenesis Embryonic Stem Cells Genetics (clinical) medicine.diagnostic_test Endothelial Cells Gene Expression Regulation Developmental Cell Differentiation Cadherins Flow Cytometry Embryonic stem cell Platelet Endothelial Cell Adhesion Molecule-1 Cell culture embryonic structures Cancer research Molecular Medicine Guideline Adherence medicine.symptom Cardiology and Cardiovascular Medicine Biomarkers Biotechnology |
Zdroj: | Journal of Cardiovascular Translational Research. 5:605-617 |
ISSN: | 1937-5395 1937-5387 |
DOI: | 10.1007/s12265-012-9379-2 |
Popis: | Revascularisation of ischaemic tissue remains an area of substantial unmet clinical need in cardiovascular disease. Strategies to induce therapeutic angiogenesis are therefore attractive. Our recent focus has been on human embryonic stem cell (hESC) strategies since hESC can be maintained in a pluripotent state or differentiated into any desired cell type, including endothelial cells (EC), under defined differentiation culture conditions. We recently published a protocol for non-good manufacturing practice (GMP) feeder- and serum-free hESC-EC-directed monolayer differentiation to vascular EC demonstrating the potential to generate hESC-derived EC in a GMP-compliant manner suitable for use in clinical trials. In this study we modified that laboratory protocol to GMP compliance. EC production was confirmed by flow cytometry, qRT-PCR and production of vascular structures in Matrigel®, yielding approximately 30 % mature VE-cadherin(+)/PECAM-1(+) cells using the GMP-compliant hESC line RC13. In conclusion, we have successfully demonstrated the production of vascular EC under GMP-compliant conditions suitable for clinical evaluation. |
Databáze: | OpenAIRE |
Externí odkaz: |